IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial

Kohli, N., Lerner, M., Rashty, J., Kirke, D., Stewart, T., & Blitzer, A. (2022). IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial. American Journal of Otolaryngology, 43(6), 103613. https://doi.org/10.1016/j.amjoto.2022.103613
Authors:
Nikita Kohli
Michael Lerner
Jamie Rashty
Diana Kirke
Thomas Stewart
Andrew Blitzer
Affiliated Authors:
Andrew Blitzer
Columbia Affiliation:
Subjects:
Botulinum Toxins, Type A (MeSH)
Dysphonia (MeSH)
Dystonia (MeSH)
Author Keywords:
laryngeal dystonia
spasmodic dysphonia
incobotulinum toxin a
elink
Publication Type:
Article
Unique ID:
10.1016/j.amjoto.2022.103613
PMID:
36055061
DOI:
10.1016/j.amjoto.2022.103613
Journal:
American Journal of Otolaryngology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: